Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Vyome Holdings, Inc. (HIND : NSDQ)

• Company Description    Vyome Therapeutics Inc. is a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases principally in the US. Vyome Therapeutics Inc., formerly known as ReShape Lifesciences Inc., is based in CAMBRIDGE, Mass. Number of Employees: 18

• Price / Volume Information    Yesterday's Closing Price: $3.44 Daily Weekly Monthly 20 Day Moving Average: 65,146 shares Shares Outstanding: 5.64 (millions) Market Capitalization: $19.42 (millions) Beta: 1.06 52 Week High: $519.00 52 Week Low: $3.26 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -32.42% -32.30% 12 Week -37.46% -38.46% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL Harvard Square One Mifflin Place Suite 400 - Cambridge,MA 02138 USA ph: 973-832-8147 fax: - vyomepr@icrinc.com https://vyometx.com

• General Corporate Information    Officers Paul F. Hickey - President and Chief Executive Officer Dan W. Gladney - Executive Chairman of the Board Thomas Stankovich - Senior Vice President and Chief Financial Officer Lori McDougal - Director Arda Minocherhomjee - Director Peer Information Vyome Holdings, Inc. (GSAC) Vyome Holdings, Inc. (CASI) Vyome Holdings, Inc. (ALCD.) Vyome Holdings, Inc. (OMNN) Vyome Holdings, Inc. (CGPI.) Vyome Holdings, Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 92943X104 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 04/03/26 Share - Related Items Shares Outstanding: 5.64 Most Recent Split Date: 8.00 (0.25:1) Beta: 1.06 Market Capitalization: $19.42 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 04/03/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 3.21 Price/Cash Flow: - Price / Sales: 4.63 EPS Growth vs. Year Ago Period: 99.00% vs. Previous Quarter: 65.33% Sales Growth vs. Year Ago Period: -98.47% vs. Previous Quarter: -97.18% ROE 12/31/25 - - 09/30/25 - -423.39 06/30/25 - -216.95 ROA 12/31/25 - - 09/30/25 - -166.02 06/30/25 - -69.42 Current Ratio 12/31/25 - - 09/30/25 - 1.94 06/30/25 - 2.77 Quick Ratio 12/31/25 - - 09/30/25 - 1.94 06/30/25 - 1.97 Operating Margin 12/31/25 - - 09/30/25 - -270.58 06/30/25 - -69.71 Net Margin 12/31/25 - - 09/30/25 - -270.58 06/30/25 - -69.71 Pre-Tax Margin 12/31/25 - - 09/30/25 - -298.45 06/30/25 - -69.33 Book Value 12/31/25 - - 09/30/25 - 1.07 06/30/25 - 9.77 Inventory Turnover 12/31/25 - - 09/30/25 - 1.26 06/30/25 - 0.92 Debt-to-Equity 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00 Debt-to-Capital 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00

Powered by Zacks Investment Research ©